<span item_type="fundamental" item_id="6a6e99cd08e28020dd45e7c7d6c37744" counter_id="ST/US/ATXI" env="prod"></span><span item_type="announcement" item_id="549445119237365377" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 1.404 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD 0.11.</p><p></p><h3>Segment Revenue</h3><ul><li>Avenue Therapeutics, Inc. generated $1.4 million in net revenue related to the AnnJi license termination and program transfer for the three months ended June 30, 2025. No revenue was recognized for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1644963/000143774925026935/atxi20250630_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income (Loss):</strong> The net income for the three months ended June 30, 2025, was $329,000 compared to a net loss of $2.7 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $1.5 million compared to $7.1 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1644963/000143774925026935/atxi20250630_10q.htm"></span></li><li><strong>Operating Expenses:</strong> Total operating expenses for the three months ended June 30, 2025, were $1.1 million, a decrease from $2.8 million in 2024. For the six months ended June 30, 2025, operating expenses were $3.0 million, down from $6.5 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1644963/000143774925026935/atxi20250630_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow:</strong> Net cash used in operating activities was $1.4 million for the six months ended June 30, 2025, compared to $5.4 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1644963/000143774925026935/atxi20250630_10q.htm"></span></li><li><strong>Financing Cash Flow:</strong> Net cash provided by financing activities was $2.1 million for the six months ended June 30, 2025, primarily due to proceeds from the sale of common stock.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1644963/000143774925026935/atxi20250630_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Research and Development Expenses:</strong> For the three months ended June 30, 2025, research and development expenses were $0.2 million, a decrease from $1.4 million in 2024. For the six months ended June 30, 2025, these expenses were $0.6 million, down from $3.8 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1644963/000143774925026935/atxi20250630_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus:</strong> Avenue Therapeutics, Inc. plans to continue developing its existing product candidates and seek regulatory approval. The company intends to obtain additional capital through the sale of debt or equity securities to fund operations and research and development activities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1644963/000143774925026935/atxi20250630_10q.htm"></span></li><li><strong>Non-Core Business:</strong> The company is exploring strategic alternatives for its Baergic subsidiary and/or BAER-101, which may involve engaging a development or licensing partner or a sale, license, or divestiture.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1644963/000143774925026935/atxi20250630_10q.htm"></span></li></ul>

Avenue Therap | 10-Q: FY2025 Q2 Revenue: USD 1.404 M